Capecitabine plus bevacizumab (Cape-Bev) as a maintenance treatment after induction treatment with FOLFIRI plus bevacizumab (FOLFIRI-Bev) in metastatic colorectal cancer (mCRC).
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31, (Summary Text)
- Publication Type: Conference Paper / Summary Text
- Volume: 31
- City: Illinois
- Country: United States Of America
- Akdeniz University Affiliated: Yes